Latest Breaking News On - Hannover medical school in - Page 1 : comparemela.com

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOz adlerYale child study centerCompany or scisparcHannover medical schoolTel aviv sourasky medical centerYale school of medicineHannover medical school inIsraeli ministry of healthExchange commissionScisparc ltdInstitute for drugsClinical trialTourette syndromeYale schoolChief executive officer

SciSparc Receives Approval to Conduct Phase IIb Clinical

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical.

Tel avivUnited statesOz adlerYale child study centerCompany or scisparcExchange commissionTel aviv sourasky medical centerHannover medical schoolScisparc ltdHannover medical school inYale school of medicineInstitute for drugsIsraeli ministry of healthFederal instituteMedical devicesHannover medical

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 .

United statesTel avivOz adlerHannover medical schoolExchange commissionYale child study centerTel aviv sourasky medical centerScisparc ltdYale school of medicineHannover medical school inInstitute for drugsIsraeli ministry of healthCompany or scisparcFederal instituteMedical devicesHannover medical

SciSparc (SPRC) Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

SciSparc (SPRC) Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tel avivUnited statesOz adlerScisparc ltdYale child study centerTel aviv sourasky medical centerCompany or scisparcIsraeli ministry of healthYale school of medicineHannover medical school inInstitute for drugsFederal instituteMedical devicesTourette syndromeHannover medical schoolYale school

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School

United statesTel avivOz adlerTel aviv sourasky medical centerInstitute for drugsIsraeli ministry of healthHannover medical school inHannover medical schoolYale school of medicineCompany or scisparcExchange commissionYale child study centerScisparc ltdFederal instituteMedical devicesHannover medical